Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research
  • Nature Research
  • Editors
  • United Kingdom
Five Corners is a Sydney based privately owned Australian CRO (Clinical Research Organisation). We provide contract services to manufacturers of medical technologies wishing to perform clinical research in Australia and New Zealand. We collaborate with international CROs, who do not have a presence in Australia or New Zealand, with clinical research services. We also provide Regulatory Consulting Services assisting clients in navigating local regulatory pathways. In addition, our other services include; Field Clinical Engineering, Quality Management System Development, Implementation and Auditing, Manuscript Development, Distributor Profiling, Reimbursement Consulting and Clinical Training. Established over 20 years ago, the clinically specialised team at Five Corners has extensive experience in clinical research and understands the obligations a Local Sponsor has in acting on behalf of an international medical device partner company. Our services are tailored to our clients depending on the current stage of development of the product and the study. Being a boutique clinical research organisation allows flexibility in our approach to meeting the needs of our clients. The Five Corners team is dedicated to providing highly specialised services to our clients within Australia and New Zealand, ensuring that they, and we, undertake activities in line with the ever increasing government and industry standards.
BioMedica Diagnostics is a proudly Canadian company focusing on thrombosis & haemostasis diagnostic solutions for human and animal health. BioMedica offers a comprehensive line of diagnostic and research products recently strengthened through an acquisition of specialty coagulation products and technologies. In the BioMedica line-up, partners will find high quality kits, controls, reagents, calibrators, antibodies and substrates that are designed for clinical use in routine and specialty coagulation and are also widely used in research and industry environments. BioMedica products are available for sale directly to laboratories and can also be purchased worldwide through a network of elite distributors. Many products are Health Canada Registered, FDA 510(k) cleared and/or CE marked. In addition to clinical partners, BioMedica also works with industry partners to OEM or customize products that are manufactured to a partner’s custom requested specifications, available in a final packaged format or as bulk intermediary product, ready for further manufacture.
Go to the profile of Vaibhav Bhardwaj
Vaibhav Bhardwaj

Business Development, Commercial Ops & Strategy, Seven Bridges

PhD in the Biological Sciences which focused on using synthetic biology tools to better understand promoter activity in bacteria. Additionally, I pursued a microbial ecology approach to investigate community behaviour between co-dependent algae and bacteria. Lastly, using NGS approaches I and my fellow lab members investigated the transcriptome profiles of these co-dependent algae-bacteria communities. Genetics, Microbiology, Microbial Ecology, Synthetic Biology, Molecular Biology, Evolution, Social Evolutionary Theory.
Go to the profile of Edurne Gil
Edurne Gil

Marketing and Communications Technician en 3P Biopharmaceuticals, 3P Biopharmaceuticals

Go to the profile of Vassilis Georgiadis, PhD
Vassilis Georgiadis, PhD

Senior Partnerships Manager, Pharma & Healthcare, University College London

Go to the profile of Freya Lowe
Freya Lowe

Community Manager, Dealslands.co.uk

Lowe Freya is working as a Community Manager at Dealslands.co.uk. In her leisure time, she really likes to share her views and her trips to various places.
Icell Kealex Therapeutics is an oncology biotech startup based at JLABS at the Texas Medical Center in Houston, Texas. We are developing oncoloytic vaccinia viruses armed with T-cell-engaging antibody fragments that boost the virus’s antitumor efficacy. This modification in the virus allows the tumor cells that are not infected with the virus to be target by T-cells. Icell Kealex has a deep pipeline of T cell engager oncolytic vaccinia virus which offer an advantage over other oncolytic viruses. We plan to enter phase 1 trials with our lead product in 2018. We are looking for co-development or licensing partnerships
ValiSeek Limited was formed as a Joint Venture single asset company in 2014 to progress cancer program VAL401 through early stage clinical trials to a stage attractive for out-licensing. ValiSeek is looking to initiate detailed licensing discussions prior to completion for co-development or out-licensing on a regional, global or disease specific basis to ensure a smooth continuation of their project VAL401.
Aposense, an Israeli publicly-traded biopharmaceutical company (TASE: APOS), is focused on a novel and powerful natural energy resource: the membrane dipole potential, a recently-discovered voltage, measurable in every leaflet of any phospholipid membrane. The dipole potential translates into an enormously strong electric field of up to 1 billion V/m (!), spanning ~30 Å, from membrane surface to membrane center. Excitingly, this electric potential, and its related internal membrane electric field (IMEF) have not been recruited to date for any medical application. Fascinated by the fact that every cell harbors its own discrete and strong powerhouse, Aposense developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities, capable of "energy mining" from the IMEF, and its translation into kinetic energy, for movement within the hydrophobic membrane core. Upon linkage to a cargo drug, this intra-mem¬brane movement of the MNMs can be utilized for energy-consuming tasks, such as enabling the delivery of siRNA into the cytoplasm, where they exert their pharmacological effects, e.g., gene silencing, or moving the drug into drug depot sites generated at the depths of the phospholipid membranes. In both scenarios, Aposense’s MNM are improving pivotal drug features.
TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.
Awaken the body’s Power™ to protect, restore & regenerate Our vision is to “Challenge, Collaborate, Create” to bring innovative, impactful therapies which simplify and increase quality of life. Temple Therapeutics BV is a Dutch domiciled privately held company. We are a clinical stage company focused on developing products that are destined to address unmet medical needs in the hospital’s acute care and surgery departments. Temple’s development focus is on modifying disease. We believe in developing products that unlock the body’s intrinsic capacity to restore balance. Hence, your body is your Temple. Our goal is to develop treatments that truly increase quality of life and ease the financial burden. Our lead asset, Evitar™ has just completed phase I/II trial and is open to partnership opportunities as we enter the pivotal phase across USA, EU and Japan, including other regional markets. FDA meeting completed, regulatory and clinical pathways determined. Currently we are at the beginning stages of our fundraising campaign to complete additional studies including pivotal by 2018.
Go to the profile of Emma Pickup
Emma Pickup

Account Executive, Sciad Communications

SCIAD is a marketing and communications agency that works with businesses in science, tech, healthcare, biotech and other science and technology-based sectors. We use integrated communications to drive up reputations and increase website traffic, connecting with the audiences that matter most by maximising the power of the web.
Two research collaborations, one with the synthetic biochemistry team at GlaxoSmithKline (GSK) and the other with the Centre for Synthetic Biology and the department of bioengineering at Imperial College, London, have Sphere Fluidics working at the cutting edge of mass spectrometry (MS) and synthetic biology. MS is the technique of choice for characterizing proteins and chemicals and for distinguishing nuances between metabolite concentrations in biological samples. Following atom ionization, the masses of the molecules and their derivatives can be determined. However, compared to other technologies used to characterize biological samples such as genome sequencing, MS is a lowthroughput process. Sphere Fluidics’ picodroplet technology now provides a high-throughput approach for analyzing single cells or a few hundred picoliters of fluid containing the molecules of interest. The technology platform is already used to support a number of applications in the academic and biopharmaceutical research communities.
Go to the profile of Alexis Romero
Alexis Romero

ESPECIALISTA EN PRODUCTOS BIOTECNOLÓGICOS DE ALTA ESPECIALIDAD

Go to the profile of Ukoha Henry Ogbonnaya
Ukoha Henry Ogbonnaya

Intern, International Institute of Tropical Agriculture (IITA)

Biochemist.
Go to the profile of Helaine Gariepy, Ph.D.
Helaine Gariepy, Ph.D.

Research Fellow - Harvard Medical School/BIDMC, Harvard Medical School

Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

Go to the profile of Georgia Francis
Georgia Francis

Senior Editorial Assistant, BioPharm Dealmakers, Springer Nature

Hi there, I'm Georgia. I am the Editorial Assistant for Biopharma Dealmakers - the quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry. The supplementary magazine appears in both Nature Biotechnology and Nature Reviews Drug Discovery. Please get in touch if you would like to feature.
Go to the profile of Bobby W Sandage Jr
Bobby W Sandage Jr

CEO, Euclises Pharmaceuticals, Inc.